Novel 1,4-dihydropyridine derivatives, process for preparing the same, and agents for treating disorders of circulatory system

The present invention relates to novel 1,4-dihydropyridine derivatives of the formula (1): ##STR4## wherein X is a halogen; R.sup.1 is a straight, branched or cyclic alkyl group having 1 to 10 carbon atoms, the group --(CH.sub.2).sub.n --Y [where n is an integer of 0 to 8, provided that n is an integer of 2 to 8 when Y is bonded to COO-- through the hetero atom; Y is a cyclic alkyl group having 3-6 carbon atoms, an aryl group having 6-10 carbon atoms, a pyrrolidinyl group, an imidazolidinyl group, a thienyl group, a furyl group, an imidazolyl group, a pyridyl group, a pyrimidinyl group, a morpholinyl group, a thiomorpholinyl group or a pyrrolizidinyl group, the group ##STR5## (where D is an aryl or aralkyl group having 6-15 carbon atoms which may be substituted by a halogenated alkyl group), or a 3-piperidinyl group substituted by a phenylalkyl group of 7-10 carbon atoms which may be substituted by one or two halogens], the group --(CH.sub.2).sub.m --O--Z (where m is an integer of 1 to 8; and Z is an alkyl or aryl group), or the group ##STR6## (where l is an integer of 1-7; A is a hydrogen atom, an alkyl group or an aryl group; and R.sup.3 and R.sup.4 which may be the same or different represent an alkyl, aryl or aralkyl group); and R.sup.2 is a lower alkyl group. The present invention also relates to pharmaceutically acceptable acid addition salts of these 1,4-dihydropyridine derivatives, as well as a process for preparing such 1,4-dihydropyridine derivatives and pharmaceutically acceptable acid addition salts, and agents which contain them as effective ingredients for treating disorders of the circulatory system.
The novel 1,4-dihydropyridine derivatives of the formula (1) exhibit superior pharmacological effects such as hypotension, peripheral vasodilation, coronary vasodilation, cerebral vasodilation, and renovascular dilation over prolonged duration while causing only low levels of side effects. Because of these advantages, the 1,4-dihydropyridine derivatives of the formula (1) are useful as hypotensives, cerebral circulation improvers and antianginal agents.
Currently it is being found that calcium antagonists (Ca.sup.++ antagonists), which had been spotlighted as new agents for treating disorders of the cardiovascular system, have a variety of pharmacological effects and are active not only against hypertension, angina pectoris, cerebral circulation disorder and arrhythmia but also in preventing arteriosclerosis and potentiating the effects of carcinostatic agents. Thus therapeutic uses of Ca.sup.++ antagonists continue to increase.
Ca.sup.++ antagonists which have been known include Nifedipine, Nicardipine, Verapamil, Diltiazem and the like.
Many studies have so far been made on Nifedipine and other dihydropyridine derivatives and they have been shown to exhibit interesting pharmacological actions such as vasodilation and hypotension. But there is room for improvement in the properties of these dihydropyridine derivatives such as duration of action, organ-selectivity, stability against light, heat, etc., and with respect to side effects.
The present inventors made concerted efforts in order to develop calcium antagonists with improvements made in the characteristics listed above. As a result, the inventors have found that the 1,4-dihydropyridine derivatives having the formula (1) shown above exhibit strong vasodilative action over prolonged duration with the utmost level of safety being ensured. The present invention has been accomplished on the basis of this finding.
In accordance with the present invention, the novel 1,4-dihydropyridine derivatives of the formula (1) and acid addition salts thereof are provided; ##STR7##
The 1,4-dihydropyridine derivatives of the formula (1) are synthesized through a route involving the formation of hydroxy-1,4-dihydropyridine derivatives of the following formula (4): ##STR8##
The hydroxy-1,4-dihydropyridine derivatives of formula (4) which are used as intermediate compounds in the process of the present invention may be synthesized by an improved version of the method described in C. F. H. Allen et al., Org. Syn. Coll., vol. 3, 377 (1955). According to this modified method, a dialkyl ester of malonic acid represented by formula (5): ##STR9## (where R.sup.2 is the same as defined above) and one equivalent amount of nitrobenzaldehyde are heated in the presence of a base such as piperidine, methyl piperidine or trialkylamine to form a benzylidenemalonic acid ester derivative of the formula (2): ##STR10## (where R.sup.2 is the same as defined above). To this benzylidenemalonic acid ester derivative (2) is added one equivalent amount of a 3-aminocrotonic acid ester derivative of the formula (3): ##STR11## (where R.sup.1 is the same as defined above) and the mixture is heated to form a benzylidene derivative of the formula (6): ##STR12## (where R.sup.1 and R.sup.2 are the same as defined above).
This benzylidene derivative (6) is heated either in the presence of a base such as triethylamine, potassium carbonate or potassium t-butoxide or, if R.sup.1 has a basic group, in the absence of any base, thereby forming a hydroxydihydropyridine derivative having the formula (4): ##STR13##
The compound of the present invention having the formula (1): ##STR14## (where X, R.sup.1 and R.sup.2 are the same as defined above) may be obtained by heating said hydroxydihydropyridine derivative (4) in the presence of a halogenating agent such as phosphorus oxychloride or phosphorus pentachloride. Throughout the process of synthesizing this dihydropyridine derivative (1), an ether-, hydrocarbon- or amide-based solvent is desirably used, with the heating temperature being desirably selected at between 60.degree. and 150.degree. C.
The ester substituent R.sup.1 at position 5 of the thus synthesized novel 1,4-dihydropyridine derivative (1) may be a straight, branched or cyclic alkyl group having 1-10 carbon atoms, the group --(CH.sub.2).sub.n --Y [where n is an integer of 0 to 8, provided that n is an integer of 2 to 8 when Y is bonded to COO-- through the hetero atom; Y is a cyclic alkyl group having 3-6 carbon atoms, an aryl group having 6-10 carbon atoms, a pyrrolidinyl group, an imidazolidinyl group, a thienyl group, a furyl group, an imidazolyl group, a pyridyl group, a pyrimidinyl group, a morpholinyl group, a thiomorpholinyl group or a pyrrolizidinyl group, the group ##STR15## (where D is an aryl or aralkyl group having 6-15 carbon atoms which may be substituted by a halogenated alkyl group), or a 3-piperidinyl group substituted by a phenylalkyl group of 7-10 carbon atoms which may be substituted by one or two halogens], the group --(CH.sub.2).sub.m --O--Z (where m is an integer of 1 to 8; and Z is an alkyl or aryl group), or the group ##STR16## (where l is an integer of 1-7; A is a hydrogen atom, an alkyl group or an aryl group; and R.sup.3 and R.sup.4 which may be the same or different represent an alkyl, aryl or aralkyl group).
After the above reaction the products of the formula (1) of this invention can be purified by using conventional methods such as adsorption column chromatography, ion-exchange chromatography or recrystallization. Alternatively, the products can be treated with an inorganic acid such as hydrochloric acid, sulfuric acid or phosphoric acid, or an organic acid such as oxalic acid, succinic acid or malic acid to convert them to salts thereof, and then can be purified by recrystallization, adsorption chromatography or ion-exchange chromatography.
The thus prepared compounds (1) of the present invention exhibit a strong vasodilative effect in isolated guinea pig hearts, strong vasodilative and hypotensive effects in anesthetized dogs, and a strong hypotensive effect in conscious spontaneously hypertensive rats (SHR), and all of these effects last longer than in the case where existing drugs such as Nicardipine are administered.
Thus, the compounds of the present invention exhibit superior coronary vasodilative effects in guinea pigs and prove very effective in dogs for increasing the blood flow of vertebral artery, reducing the vascular resistance of vertebral artery and lowering the systemic blood pressure. Because of these effects, the compounds of the present invention will be useful in treating angina pectoris (myocardial infarction), disturbances of cerebral circulation, and hypertension.
The compounds (1) of the present invention can be administered alone or in combination with excipients in a variety of dosage forms such as tablets, troches, pills, granules, powders, capsules, ampules, suppositories and the like. The excipients include, for example, starch, dextrin, sucrose, lactose, silicic acid, carboxymethylcellulose, cellulose, gelatin, polyvinylpyrrolidone, glycerin, agar, calcium carbonate, sodium bicarbonate, paraffin, cetyl alcohol, stearic acid esters, kaolin, bentonite, talc, calcium stearate, magnecium stearate, polyethyleneglycol, water, ethanol, isopropylalcohol, propyleneglycol and the like.
For parenteral administration, the compounds of this invention are converted into water soluble salts thereof and the salts are dissolved in sterile distilled water or sterile physiological saline and are filled in ampules to be used for injection. If necessary, stabilizing agents and/or buffering agents can be included in the ampules.
For oral administration, the optimum dose range of the compound (1) of this invention is 5-500 mg per day for an adult. Of course, this dose range can be suitably changed depending upon the characteristics of the subjects including age, response, body weight, severity of disease etc.
The present invention can be illustrated by the following working examples and referential examples but it should be understood that it is not limited to them.
REFERENTIAL EXAMPLE A-a
2-Hydroxy-3,5-dimethoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (1)] ##STR17##
Methyl acetoacetate (5.0 g) was dissolved in methanol (20 ml) and after addition of a concentrated (28%) aqueous ammonia solution (5 ml), the mixture was heated under reflux for 16 hours. After completion of the reaction, the solvent was distilled off and the residue was subjected to extraction with chloroform, yielding 4.75 g (95.8%) of colorless needles. The needles (151 mg) and dimethyl 3-nitrobenzylidenemalonate (318 mg) were dissolved in anhydrous ethanol (13 ml) and the mixture was heated under reflux for 4.5 hours. The reaction mixture was cooled to room temperature to obtain 285 mg of crystals E. A portion (175 mg) of the crystals E was dissolved in 6 ml of anhydrous methanol and, after addition of triethylamine (1.5 ml), the mixture was heated under reflux for 16 hours. After the solvent was distilled off under reduced pressure, the residue was subjected to silica gel column chromatography (elution solvent: 2% chloroform/methanol) and the resulting crude crystals were recrystallized from a solution of chloroform/ether to obtain 152 mg (yield: 95.0%) of the desired compound (m.p. 150.degree.-152.degree. C.).
The following compounds were synthesized in accordance with the method of Referential Example A-a:
5-[2-(4-benzhydrylpiperazin-1-yl)ethyl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (3)];
5-[2-(N-benzyl-N-methylamino)ethyl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (4)];
5-[2-{4-(9-fluorenyl)piperazine-1-yl}ethyl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (5)];
2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-5-(5-phenylpentyloxycarbonyl)-1,4-dihydropyridine [Compound (6)];
2-hydroxy-5-isopropoxycarbonyl-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (7)];
5-[1-(4-fluorobenzyl)-3-piperidyl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (8)];
5-n-heptyloxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (9)];
2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-5-(2-phenoxy)ethyloxycarbonyl-1,4-dihydropyridine [Compound (10)];
5-cyclopropylmethyloxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (12)];
2-hydroxy-3-methoxycarbonyl-6-methyl-5-[2-(N-benzyl-N-methylamino)-1-phenylethyl]oxycarbonyl-4-(3-nitrophenyl)-3-methoxycarbonyl-1,4-dihydropyridine [Compound (13)];
2-hydroxy-3-methoxycarbonyl-5-(2-methoxyethyl)oxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (14)]; and
2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-5[2-(2-pyridyl)ethyl]oxycarbonyl-1,4-dihydropyridine [Compound (17)].
The physicochemical data of compound (1) and of the above-listed compounds are shown in Table A.
REFERENTIAL EXAMPLE A-b
2-Hydroxy-3,5-dimethoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine [Compound (1)]
Crystals E (1.33 g) obtained during synthesis according to Referential Example A-a were dissolved in 20 ml of anhydrous dimethylformamide. The resulting solution was added to 2.42 g of anhydrous potassium carbonate and the mixture was stirred at 80.degree. C. for 2.5 hours. The reaction mixture was poured into ice water and subjected to extraction with ether. The extract was distilled off to obtain crude crystals. This crude crystals were recrystallized from chloroform-ether to obtain 1.10 g (91%) of the desired compound.
After reaction was performed in accordance with Referential Example A-b, the extract was distilled off and the residue was subjected to silica gel column chromatography (elution solvent: 1% chloroform/methanol) to thereby obtain 3-ethoxycarbonyl-2-hydroxy-6-methyl-5-[5-(morpholino)ethel]oxycarbonyl-4-(2-nitrophenyl)-1,4-dihydropyridine [Compound (15)].
The physicochemical data of this compound are shown in Table A. ##STR18##
REFERENTIAL EXAMPLE B
2-Hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-5-{2-(2-thienyl)ethoxycarbonyl}-1,4-dihydropyridine [Compound (11)] ##STR19##
A mixture of 2-(2-thienyl)ethyl 3-amino-2-butenoate (1.8 g) and dimethyl 3-nitrobenzylidenemalonate (2.25 g) was dissolved in anhydrous 2-propanol (80 ml) and, after addition of triethylamine (27 ml), the mixture was refluxed for 21 hours. After the solvent was distilled off under reduced pressure, the residue was purified by thin-layer silica gel chromatography (developing solvent: chloroform/methanol=19/1; elution solvent: chloroform/acetone=2/1) so as to obtain 1.0 g (26%) of the desired compound.
The physicochemical data of this compound are shown in Table A.
REFERENTIAL EXAMPLE C
2-Hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-5-(8-pyrrolizidinyl)methoxycarbonyl-1,4-dihydropyridine [Compound (16)] ##STR20##
A mixture of 2-pyrrolizidinylmethyl 3-amino-2-butenoate (0.19 g) and dimethyl 3-nitrobenzylidenemalonate (0.23 g) was dissolved in 15 ml of anhydrous 2-propanol, and the mixture was heated under reflux for 22 hours. After the solvent was distilled off under reduced pressure, the residue was subjected to silica gel column chromatography (elution solvent: 5% chloroform/methanol), thereby obtaining 0.32 g (82.1%) of the desired compound.
By repeating the method of Referential Example C, 3,5-dimethoxycarbonyl-2-hydroxy-6-methyl-4-(2-nitrophenyl)-1,4-dihydropyridine [Compound (2)] was obtained.
The physicochemical data of the Compounds (16) and (2) are shown in Table A.
TABLE A__________________________________________________________________________ ##STR21## IRCompound No. Spectrum(Ref. Ex. No. Compound (cm.sup.-1) asshowing method (position of Yield measured NMR Spectrum High-resolutionof synthesis) nitro group) (%) Description in CHCl.sub.3 (CDCl.sub.3, 5 ppm, 270 mass__________________________________________________________________________ spectrum1 (3-nitro group) 95 mp 150-152.degree. 3390 2.47(3H,s), 3.59(1H,s), C.sub.16 H.sub.16 N.sub.2 O.sub.7 (A-a) (chloroform/ether) 1740 3.66(3H,s), 3.81(3H,s), cal'd: 348.3140 A-a R.sup.1 = methyl group 91 pale yellow 1705 4.79(1H,s), 7.47-8.13(4H,m) found: 348.3138A-b R.sup.2 = methyl group (A-b) crystals2 (2-nitro group) 24 mp 180-184.degree. 3400 2.48(3H,s), 3.56(3H,s) C.sub.16 H.sub.16 N.sub.2 O.sub.7(C) R.sup.1 = methyl group (chloroform/ 1740 3.82(3H,s), 3.85(1H,s), cal'd: 348.3140 R.sup.2 = methyl group n-hexane) 1710 5.18(1H,s), 7.21-7.92(4H,m) found: 348.3142 pale yellow crystals3 (3-nitro group) 94 colorless 3390 2.2-2.6(3H,m), 2.46(3H,s), C.sub.34 H.sub.36 N.sub.4 O.sub.7(A-a) R.sup.1 = 2-(4-benzhydryl-1- powder 1740 2.52(2H,t,J=6Hz), cal'd: 612.6861 piperazihyl)ethyl group 1710 3.77(3H,s), 4.14(1H,s), found: 612.6866 R.sup.2 = methyl group 4.2-4.3(2H,m), 4.76(1H,s), 7.1-8.1(14H,m)4 (3-nitro group) 62 pale yellow 3395 2.12(3H,s), 2.44(3H,s), C.sub.25 H.sub.27 N.sub.3 O.sub.7(A-a) R.sup.1 = 2-(Nbenzyl-N oil 1740 2.58(2H,t,J=6Hz), cal'd: 481.5080 methylamino)ethyl 1710 3.60(1H,s), 3.79(3H,s), found: 481.5081 group 4.20(2H,t,J=6Hz), 4.80(1H,s), R.sup.2 = methyl group 7.2-8.1(9H,m), 8.72(1H,s)5 (3-nitro group) 79 pale yellow 3390 2.2-2.65(10H,m), C.sub.34 H.sub.34 N.sub.4 O.sub.7(A-a) R.sup.1 = 2-[4-(9-fluorenyl)- powder 1740 3.55(1H,s), 3.75(3H,s), cal'd: 610.6703 1-piperazinyl]ethyl 1710 4.1-4.25(2H,m), found: 610.6701 group 4.80(1H,s), 7.2-8.2(12H,m) R.sup.2 = methyl group6 (3-nitro group) 41 pale yellow 3400 1.30-1.75(6H,m), C.sub.36 H.sub.38 N.sub.2 O.sub.7(A-a) R.sup.1 = 5-phenylpentyl oil 1720 2.52(2H,t,J=7Hz), cal'd: 480.5203 group 1710 4.05(2H,t,J=7Hz), found: 480.5219 R.sup.2 = methyl group 7.10-8.20(9H,m)7 (3-nitro group) 88 mp 152-154.degree. 3390 1.05(3H,s), 1.23(3H,s), C.sub.18 H.sub.20 N.sub.2 O.sub.7(A-a) R.sup.1 = isopropyl group (CHCl.sub.3 /n-hexane) 1740 2.45(3H,s), 3.60(1H,s), cal'd: 376.3679 R.sup.2 = methyl group pale yellow 1700 3.81(3H,s), 4.77(1H,s), found: 376.3683 Crystals 4.8-5.1(1H,m), 7.4-8.3(4H,m)8 (3-nitro group) 75 pale yellow 3395 As 1:1 isomeric C.sub.27 H.sub.28 FN.sub.3 O.sub.7(A-a) R.sup.1 = 1-(4-fluorobenzyl)- oil 1745 1.1-2.7(8H,m), 2.45 and cal'd: 525.5366 3-piperidyl group 1710 (total 6H, each s), 3.3- found: 525.5371 R.sup.2 = methyl group (2H,m), 3.59 and 3.60(total 2H, each s), 4.82(1H,s), 4.8-4.95(1H,m), 6.9-8.2(8H,m)9 (3-nitro group) 62 pale yellow 3400 0.85(3H,t,J=7Hz), C.sub.22 H.sub.28 N.sub.2 O.sub.7(A-a) R.sup.1 = n-heptyl group oil 1720 1.10-1.80(10H,m), cal'd: 432.4757 R.sup.2 = methyl group 1705 3.81(3H,s), 4.05(2H,t,J=7Hz), found: 432.4759 4.78(1H,s), 7.42-8.30(4H,m)10 (3-nitro group) 33 pale yellow 3400 2.47(3H,s), 3.79(3H,s) C.sub.23 H.sub.22 N.sub.2 O.sub.8(A-a) R.sup.1 = 2-phenyloxyethyl oil 1720 3.90-4.30(2H,m), cal'd: 454.4389 group 1710 4.30-4.60(2H,m), found: 454.4391 R.sup.2 = methyl group 4.79(1H,s), 6.75-8.30(9H,m)11 (3-nitro group) 26 pale yellow 3400 2.44(3H,s), 3.07(2H,t,J=6Hz), C.sub.21 H.sub.20 N.sub.2 O.sub.7 S(B) R.sup.1 = 2-(2-thienyl)ethyl oil 1720 3.80(3H,s), 4.20-4.40(2H,m), cal'd: 444.4654 group 1710 4.77(1H,s), 6.68-8.20(7H,m) found: 444.4656 R.sup.2 = methyl group12 (3-nitro group) 50 pale yellow 3400 0.10-0.25(2H,m), C.sub.19 H.sub.20 N.sub.2 O.sub.7(A-a) R.sup.1 = cyclopropylmethyl oil 1720 0.40-0.60(2H,m), cal'd: 388.3791 group 1710 0.95-1.10(1H,m), found: 388.3789 R.sup.2 = methyl group 2.48(3H,s), 3.82(3H,s), 3.90(2H,d,J=7Hz), 4.81(1H,brs), 7.45-8.20(4H,m)13 (3-nitro group) 11 pale yellow 3380 2.02(3H,s), 2.45(3H,s), C.sub.31 H.sub.31 N.sub.3 O.sub.7(A-a) R.sup.1 = 2-(Nbenzyl-N oil 1710 2.40-2.75(2H,m), calc'd: 557.6065 methylamino)-1- 3.28(1H,d,J=10Hz), found: 557.6064 phenylethyl group 3.38(1H,d,J=10Hz), 3.76(3H,s), R.sup.2 = methyl group 4.93(1H,s), 5.97(1H,d,d,J= 8Hz, 5Hz), 6.98-8.20(14H,m)14 (3-nitro group) 98 mp 135-136.degree. 3390 2.45(3H,s), 3.26(3H,s), C.sub.18 H.sub.20 N.sub.2 O.sub.8(A-a) R.sup.1 = methoxyethyl (CHCl.sub.3 /n-hexane) 1740 3.4-3.6(2H,m), 3.60(1H,s) cal'd: 392.3673 group colorless 1700 3.81(3H,s), 4.1-4.3(2H,m), found: 392.3669 R.sup.2 = methyl group crystal 4.79(1H,s), 7.4-8.2(4H,m), 8.70(1H,s)15 (2-nitro group) 51 pale yellow 3400 1.31(3H,t,J=7Hz), C.sub.22 H.sub.27 N.sub.3 O.sub.8(A-b) R.sup.1 = 2-(morpholino)- oil 1720 2.20-2.55(6H,m), cal'd: 461.4739 ethyl group 1705 3.55(4H,t,J=5Hz), found: 461.4741 R.sup.2 = ethyl group 4.00-4.35(4H,m), 5.17(1H,s), 7.22-8.00(4H,m)16 (3-nitro group) 82 pale yellow 3390 1.2-1.8(8H,m), C.sub.23 H.sub.27 N.sub.3 O.sub.7(C) R.sup.1 = 8-pyrrolizydine- oil 1740 2.4-2.6(2H,m), 2.51(3H,s), cal'd: 457.4857 methyl group 1705 2.9-3.1(2H,m), 3.58(1H,s), found: 457.4862 R.sup.2 = methyl group 3.81(3H,s), 3.89(2H,s), 4.83(1H,s), 7.5-8.2(4H,m), 7.78(1H,brs)17 (3-nitro group) 85 colorless 3410 2.36(3H,s), 3.02(2H,t,J=6Hz), C.sub.22 H.sub.21 N.sub.3 O.sub.7(A-a) R.sup.1 = 2-(2-pyridyl)- oil 1750 3.52(1H,s), 3.78(3H,s), cal'd: 439.4271 ethyl group 1720 4.49(2H,t,J=6Hz), found: 439.4273 R.sup.2 = methyl group 6.9-8.5(8H,m), 8.72(1H,brs)__________________________________________________________________________

EXAMPLE 1
5-[2-(4-Benzhydrylpiperazin-1-yl)ethyl]oxycarbonyl-2-chloro-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine (Compound No. SUN 4752) ##STR22##
5-[2-(4-Benzhydrylpiperazin-1-yl)ethyl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine (390 mg) was dissolved in phosphorus oxychloride (5 ml) and the mixture was heated under reflux for 3 hours and 10 minutes. After excess phosphorus oxychloride had been distilled off under reduced pressure, the reaction mixture was diluted with saturated potassium carbonate and subjected to extraction with chloroform. The extract was distilled off and the residue was subjected to silica gel column chromatography (elution solvent: 1% chloroform/methanol), thereby obtaining crude crystals. This crude crystals were recrystallized from a solution of chloroform/isopropylether/hexane to yield 210 mg (57.2%) of the desired compound.
EXAMPLE 2
2-Chloro-5-[1-(4-fluorobenzyl)piperidin-3-yl]oxycarbonyl-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydroppyridine (Compound No. SUN 5142) ##STR23##
5-[1-(4-fluorobenzyl)piperidin-3-yl]oxycarbonyl-2-hydroxy-3-methoxycarbonyl-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine (1.85 g) was dissolved in phosphorus oxychloride (22 ml) and the mixture was heated under reflux for 3 hours. After excess phosphorus oxychloride had been distilled off under reduced pressure, the reaction mixture was diluted with saturated potassium carbonate and subjected to extraction with chloroform. The extract was distilled off and the residue was subjected to silica gel column chromatography (elution solvent: 0.7-2.5% chloroform/methanol) and to alumina column chromatography (elution solvent: chloroform/hexane=3/2), so as to obtain 0.98 g (51.3%) of the desired compound.
The physicochemical data of SUN 4752 and SUN 5142 are shown in Table 1.
Additional compounds were synthesized by repeating Examples 1 and 2 and their physicochemical data are shown in Table 1 together with the respective compound numbers.
TABLE 1__________________________________________________________________________ ##STR24## IRCompound No. Spectrum(Ref. Ex. No. (cm.sup.-1) asshowing method Compound Yield measured NMR Spectrum High-resolutionof synthesis) (position of nitro group) (%) Description in CHCl.sub.3 (CDCl.sub.3, 5 ppm, 270 mass__________________________________________________________________________ spectrumSUN (3-nitro group) 44 mp 225-228.degree. 3420 2.40(3H,s), 3.66(1H,s), C.sub.16 H.sub.15 ClN.sub.2 O.sub.64616 R.sup.1 = methyl group (CHCl.sub.3 /n-hexane) 1700 3.70(3H,s), 5.25(1H,s), cal'd: 574.0566 R.sup.2 = methyl group pale yellow 6.08(1H,s), 7.39-8.12(4H,m) found: 574.0561 crystalsSUN (2-nitro group) 6 mp 162-164.degree. 3425 2.36(3H,s), 3.60(3H,s) C.sub.16 H.sub.15 ClN.sub.2 O.sub.64671 R.sup.1 = methyl group (CHCl.sub.3 /n-hexane) 1700 3.65(3H,s), 5.87(1H,s), cal'd: 574.0566 R.sup.2 = methyl group pale yellow 5.95(1H,s), 7.28-7.73(4H,m) found: 574.0570 crystalsSUN (3-nitro group) 57 mp 131-134.degree. 3425 2.3-2.6(8H,m), 2.38(3H,s), C.sub.34 H.sub.35 ClN.sub.4 O.sub.64752 R.sup.1 = 2-(4-benzhydryl-1- (CHCl.sub.3 / 1700 2.5-2.7(2H,m), 3.67(3H,s), cal'd: 631.1318 piperazinyl)ethyl group isopropylether/ 4.1-4.2(2H,m), 4.19(1H,s), found: 631.1324 R.sup.2 = methyl group n-hexane) 5.23(1H,s), 6.07(1H,s), pale yellow 7.1-8.1(14H,m) crystalsSUN (3-nitro group) 14 pale yellow 3425 2.20(3H,s), 2.37(3H,s), C.sub.25 H.sub.26 ClN.sub.3 O.sub.65017 R.sup.1 = 2-(Nbenzyl-N oil 1700 2.5-2.7(2H,m), 3.50(1H,s), cal'd: 499.9537 methylamino)ethyl 3.69(3H,s), 4.18(2H,t,J=6Hz), found: 499.9532 group 5.27(1H,s), 6.27(1H,s), R.sup.2 = methyl group 7.2-8.2(9H,m),SUN (3-nitro group) 33 pale yellow 3425 2.3-2.7(10H,m), C.sub.34 H.sub.33 ClN.sub.4 O.sub.65018 R.sup.1 = 2-[4-(9-fluorenyl)- powder 1700 3.65(3H,s), 4.05-4.25(2H,m), cal'd: 629.1160 1-piperazinyl]ethyl (mp 110-150.degree.) 4.82(1H,s), 5.22(1H,s), found: 629.1156 group 6.39(1H,s), 7.2-8.2(12H,m) R.sup.2 = methyl groupSUN (3-nitro group) 48 pale yellow 3420 1.40-1.80(6H,m), C.sub.26 H.sub.27 ClN.sub.2 O.sub.65088 R.sup.1 = 5-phenylpentyl oil 1710 2.56(2H,t,J=7Hz), cal'd: 498.9660 group 1695 3.70(2H,t,J=7Hz), found: 498.9659 R.sup.2 = methyl group 7.10-8.30(9H,m)SUN (3-nitro group) 11 mp 161-165.degree. 3430 1.10(3H,d,J=6.5Hz), C.sub.18 H.sub.19 ClN.sub.2 O.sub.65141 R.sup.1 = isopropyl group (CHCl.sub.3 /ether/ 1700 1.26(3H,d,J=6.5Hz), cal'd: 394.8136 R.sup.2 = methyl group n-hexane) 2.38(3H,s), 3.70(3H,s), found: 394.8142 colorless 4.97(1H,quintet,J=6Hz), crystals 5.22(1H,s), 6.30(1H,s), 7.4-8.1(4H,m)SUN (3-nitro group) 51 colorless 3450 As 1:1 isomeric C.sub.27 H.sub.27 ClN.sub.3 O.sub.65142 R.sup.1 = 1-(4-fluorobenzyl)-3- powder 1700 1.2-2.8(8H,m), 2.36(3H,s), cal'd: 543.9823 piperidyl group 3.3- 3.65(2H,m), 3.71 found: 543.9819 R.sup.2 = methyl group 3.72(total 6H, each s), 4.7-4.9(1H,m), 5.23(1H,s), 6.37(1H,s), 6.9-8.2(8H,m)SUN (3-nitro group) 30 pale yellow 3400 0.87(3H,t,J=7Hz), C.sub.22 H.sub.27 ClN.sub.2 O.sub.65143 R.sup.1 = n-heptyl group powder 1700 1.15-1.75(10H,m), cal'd: 450.9214 R.sup.2 = methyl group 1695 3.71(3H,s), 3.98-4.24(2H,m), found: 450.9220 5.25(1H,s), 7.42(1H,t,J=8Hz), 7.65(1H,d,J=8Hz), 8.04(1H,d,J=8Hz), 8.14(1H,s)SUN (3-nitro group) 8 pale yellow 3420 2.40(3H,s), 3.68(3H,s), C.sub.23 H.sub.21 ClN.sub.2 O.sub.65151 R.sup.1 = 2-phenyloxyethyl oil 1705 4.05-4.20(2H,m), cal'd: 472.8846 group 4.30-4.55(2H,m), found: 472.8851 R.sup.2 = methyl group 6.80-8.15(9H,m)SUN (3-nitro group) 9 pale yellow 3430 2.36(3H,s), 3.12(2H,t,J=6Hz), C.sub.21 H.sub.19 ClN.sub.2 O.sub.6 S5163 R.sup.2 = 2-(2-thienyl)ethyl oil 1710 3.71(3H,s), 4.31(2H,t,J=6Hz), cal'd: 462.9111 group 1700 5.24(1H,s), 6.76-8.20(7H,m) found: 462.9108 R.sup.2 = methyl groupSUN (3-nitro group) 5 pale yellow 3440 0.10-0.30(2H,m), C.sub.19 H.sub.19 ClN.sub.2 O.sub.65164 R.sup.1 = cyclopropylmethyl oil 1715 0.50-0.60(2H,m), cal'd: 654.1867 group 1705 1.00-1.18(1H,m), found: 654.1866 R.sup.2 = methyl group 3.70(3H,s), 5.27(1H,s), 7.38-8.24(4H,m)SUN (3-nitro group) 39 pale yellow 3430 2.08(3H,s), 2.36(3H,s), C.sub.31 H.sub.30 ClN.sub.3 O.sub.65181 R.sup.1 = 2-(Nbenzyl-N oil 1710 2.55-2.78(2H,m), cal'd: 576.0522 methylamino)-1- 1700 3.33(1H,d,J=10Hz), found: 576.0526 phenylethyl group 3.40(1H,d,J=10Hz), 3.71(3H,s), R.sup.2 = methyl group 5.32(1H,s), 5.99(1H,m), 7.00-8.25(14H,m)SUN (3-nitro group) 2 pale yellow 3440 2.39(3H,s), 3.34(3H,s), C.sub.18 H.sub.19 ClN.sub.2 O.sub.75220 R.sup.1 = meythoxyethyl group oil 1710 3.5-3.6(2H,m), 3.69(3H,s), cal'd: 410.8130 R.sup.2 = methyl group 4.1-4.3(2H,m), 5.26(1H,s), found: 410.8135 6.31(1H,s), 7.3-8.2(4H,m)SUN (2-nitro group) 16 pale yellow 3430 1.19(3H,t,J=7Hz), C.sub.22 H.sub.26 ClN.sub.3 O.sub.75252 R.sup.1 = 2-(morpholino)- oil 1705 2.20-2.60(6H,m), cal'd: 479.9196 ethyl group 1700 3.61(4H,t,J=5Hz), found: 479.9201 R.sup.2 = ethyl group 4.00-4.30(4H,m), 5.95(1H,s) 7.25-7.80(4H,m)SUN (3-nitro group) 8 pale yellow 3425 1.2-1.9(8H,m), 2.43(3H,s), C.sub.23 H.sub.26 ClN.sub.3 O.sub.65334 R.sup.1 = 8-pyrrolizydine- oil 1700 2.5-2.7(2H,m), cal'd: 475.9314 methyl group 2.9-3.1(2H,m), 3.72(3H,s), found: 475.9309 R.sup.2 = methyl group 3.80(2H,s), 5.29(1H,s), 6.15(1H,brs), 7.4-8.2(4H,m)SUN (3-nitro group) 59 pale yellow 3440 2.30(3H,s), C.sub.22 H.sub.20 ClN.sub.3 O.sub.65336 R.sup.1 = 2-(2-pyridyl)ethyl crystals 1705 3.10(2H,t,J= 6.5Hz), cal'd: 457.8728 group (CHCl.sub.3 /n-hexane) 3.69(3H,s) found: 457.8733 R.sup.2 = methyl group mp 114-116.degree. 4.49(2H,t,J= 6.5Hz), 5.15(1H,s), 7.1-8.6(8H,m)__________________________________________________________________________
EXAMPLE 3
The coronary vascular dilative effect of selected 2-chloro-1,4-dihydropyridine derivatives of the present invention was tested.
Test method:
Hartley guinea pigs (weight 400-500 g) were killed by a blow on the head and their hearts were immediately isolated. The hearts were perfused with Krebs-Henseleit solution bubbled with a mixture of 95% O.sub.2 +5% CO.sub.2 and maintained at 37.degree. C. at a constant rate of 6 ml/minute according to Langendorff's method [J. Pharmacol. Methods 2, 143 (1979)]. The perfusion pressure was measured continuously by a pressure transducer. Samples were prepared by emulsifying 1 mg of a test compound in 1 ml of a mixture of dimethylsulfoxide and physiological saline solution (1:9) and diluting with physiological saline solution to the predetermined concentration. 0.1 ml of the diluted solution was administered into the coronary artery via rubber tube connected to an aorta cannula to obtain ED.sub.50 (.mu.g/heart) data as shown in Table 2. The numbers of the compounds in the Table correspond respectively to those of the working examples described above.
TABLE 2______________________________________Compound No. ED.sub.50 (.mu.g/heart)______________________________________SUN 5141 0.05SUN 5142 0.03SUN 5143 0.02______________________________________
EXAMPLE 4
The pharmacological effect (ED.sub.30) of selected 2-chloro-1,4-dihydropyridine derivatives of the present invention with respect to the vascular resistance of the vertebral artery in anesthetized dogs was treated by the following procedures.
Test Method:
Adult dogs of either sex (7-14 kg in body weight) were anesthetized with at first thiopental sodium (35 mg/kg, intraperitoneal), anesthetized with urethane (400 mg/kg, intravenous) and .alpha.-chloalose (60 mg/kg, intravenous) and kept under artificial respiration throughout the experiment. After thoracotomy at the left first intercostal space, the vertebral artery was exposed and blood flow was measured with an intracorporeal flow probe connected to an electromagnetic flowmeter (MF-27, Nihon Kohden).
At the same time, continuous measurement of the following parameters was made: systemic blood pressure (mean pressure) at the right femoral artery, the limb lead II ECG, the heart rate with a tachometer triggered by the R wave of ECG, and the vascular resistance determined by loading an electronic divider (EO-601 G, Nihon Kohden) with the mean values of blood pressure and vertebral artery blood flow. All of these parameters were recorded simultaneously on a polygraph (RM-600, Nihon Kohden).
All the test compounds were injected through a cannula inserted into the femoral vein.
The ED.sub.30 (.mu.g/kg) values obtained by intravenous injection and the values of T.sub.1/2 (min) (the time to reach 50% of the resistance drop) are shown in Table 3, wherein the Compound Numbers are keyed to the Example Numbers.
TABLE 3______________________________________Compound No. ED.sub.30 (.mu.g/kg) T.sub.1/2 (min)______________________________________SUN 4616 1.2 --SUN 4671 0.59 --SUN 4752 3.0 >30SUN 5017 3.3 17.0SUN 5018 4.3 15.5SUN 5088 1.4 17.0SUN 5141 0.28 10.6SUN 5142 2.8 >30SUN 5143 2.2 20.5SUN 5151 3.6 10.5SUN 5163 9.3 14.0SUN 5164 0.22 --SUN 5181 2.1 --SUN 5220 5.8 13.5SUN 5252 3.6 --______________________________________
EXAMPLE 5
Selected compounds of the present invention were tested for their hypotensive action in conscious spontaneously hypertensive rats (SHR).
Test method:
A group of 17 to 20-week old male SHR were anesthetized with ether and a cannula was inserted into the left femoral artery. At least one day after the operation, the cannula was connected to a pressure transducer and the blood pressure was measured continuously under conscious and unrestrained condition, thereby obtaining the data shown in Table 4. Each of the test compounds as a clear suspension in 0.5% CMC-Na was administered orally at a dose of 10 mg/kg (body weight) to each animal which was starved overnight.
TABLE 4______________________________________ Blood pressure drop (%)Compound No. Maximum drop 6 hours______________________________________SUN 4752 35 30SUN 5141 51 33Nicardipine 39 10-20______________________________________
EXAMPLE 6
The acute toxicity (LD.sub.50) data of selected compounds of the present invention as administered to two groups of male mice were obtained and the results are shown in Table 5. One group of mice which received peroral administration had been starved overnight. Each of the test compounds was suspended in 0.5% CMC-Na for peroral administration, or dissolved in dimethyl sulfoxide and diluted with physiological saline solution for intravenous injection.
TABLE 5______________________________________ LD.sub.50 (mg/kg)Compound No. i.v. p.o.______________________________________SUN 4752 23-27 1000SUN 5141 80 --Nicardipine 12.2 455______________________________________
The compounds of this invention have a strong and long-lasting vasodilative effect. Therefore, said compounds are considered to be useful as agents for causing coronary vascular dilation or treating hypertension or disturbances of cerebral circulation. Such disorders can be treated by administering the compound of the present invention, at a low dose level and at infrequent interval. This will make sure that the intended treatment can be done safely and easily.

Number	Name	Date
3974275	Bosset et al.	Aug 1986
4145432	Sato	Mar 1979
4423052	Araki et al.	Dec 1983

Novel 1,4-dihydropyridine derivatives, process for preparing the same, and agents for treating disorders of circulatory system

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US

International Classifications

Abstract

Description

Claims

Priority Claims (1)

US Referenced Citations (3)

Foreign Referenced Citations (1)